140480-89-3 Usage
Description
3,5-Difluorobenzenesulfonamide is a fluorinated benzenesulfonamide compound that functions as a carbonic anhydrase (CA) inhibitor. It is known for its ability to bind to human carbonic anhydrase I, forming a 1:1 complex, which makes it a significant compound in the field of pharmaceuticals and biochemistry.
Uses
Used in Pharmaceutical Industry:
3,5-Difluorobenzenesulfonamide is used as a CA inhibitor for its ability to inhibit the activity of carbonic anhydrase enzymes. This inhibition can be beneficial in treating various medical conditions, such as glaucoma, epilepsy, and altitude sickness, where the regulation of CA activity is crucial.
Used in Biochemical Research:
In the field of biochemistry, 3,5-difluorobenzenesulfonamide serves as a valuable research tool. It is used to study the structure, function, and regulation of carbonic anhydrase enzymes, which play a vital role in numerous physiological processes, including respiration, pH regulation, and ion transport.
Used in Drug Development:
3,5-Difluorobenzenesulfonamide is also utilized in the development of new drugs targeting carbonic anhydrase-related diseases. Its inhibitory properties make it a potential candidate for the design and synthesis of novel therapeutic agents that can modulate CA activity for specific medical applications.
Used in Diagnostic Applications:
3,5-DIFLUOROBENZENESULFONAMIDE can be employed in diagnostic procedures to detect and monitor the activity of carbonic anhydrase enzymes in patients. By measuring the inhibition of CA activity by 3,5-difluorobenzenesulfonamide, healthcare professionals can gain insights into the patient's condition and make informed decisions regarding treatment options.
Check Digit Verification of cas no
The CAS Registry Mumber 140480-89-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,0,4,8 and 0 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 140480-89:
(8*1)+(7*4)+(6*0)+(5*4)+(4*8)+(3*0)+(2*8)+(1*9)=113
113 % 10 = 3
So 140480-89-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H11FO5/c7-3-4(9)2(1-8)12-6(11)5(3)10/h2-6,8-11H,1H2
140480-89-3Relevant articles and documents
Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays
Huang, Boshi,Wang, Xueshun,Liu, Xinhao,Chen, Zihui,Li, Wanzhuo,Sun, Songkai,Liu, Huiqing,Daelemans, Dirk,De Clercq, Erik,Pannecouque, Christophe,Zhan, Peng,Liu, Xinyong
, p. 4397 - 4406 (2017/07/22)
Crystallographic overlap studies and pharmacophoric analysis indicated that diarylpyrimidine (DAPY)-based HIV-1 NNRTIs showed a similar binding mode and pharmacophoric features as indolylarylsulfones (IASs), another class of potent NNRTIs. Thus, a novel series of DAPY-IAS hybrid derivatives were identified as newer NNRTIs using structure-based molecular hybridization. Some target compounds exhibited moderate activities against HIV-1 IIIB strain, among which the two most potent inhibitors possessed EC50 values of 1.48?μM and 1.61?μM, respectively. They were much potent than the reference drug ddI (EC50?=?76.0?μM) and comparable to 3TC (EC50?=?2.54?μM). Compound 7a also exhibited the favorable selectivity index (SI?=?80). Preliminary structure-activity relationships (SARs), structure-cytotoxicity relationships, molecular modeling studies, and in silico calculation of physicochemical properties of these new inhibitors were also discussed.
TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY
-
Page/Page column 154-155, (2012/01/30)
The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise
